Journal: Drug Design, Development and Therapy
Article Title: GLUT5-Driven Gut-Liver Axis Injury Mediating Olanzapine-Induced NAFLD and Dapagliflozin Intervention
doi: 10.2147/DDDT.S584833
Figure Lengend Snippet: Dapagliflozin reversed GLUT5/AMPK/mTOR to improve intestinal barrier injury. ( A ) Flow chart. ( B ) AB-PAS/PAS staining in ileum and colon. ( C ) Corresponding statistical analysis of PAS staining in ileum. ( D ) Corresponding statistical analysis of PAS staining in colon. ( E ) Western blotting of GLUT5, p-AMPK, p-mTOR in intestinal tract. ( F ) Corresponding statistical analysis of GLUT5 from Western blotting in intestinal tract. ( G ) Corresponding statistical analysis of p-AMPK from Western blotting in intestinal tract. ( H ) Corresponding statistical analysis of p-mTOR from Western blotting in intestinal tract. ( I ) Western blotting of occludin, claudin-1, ZO-1. ( J ) Corresponding statistical analysis of occludin from Western blotting. ( K ) Corresponding statistical analysis of claudin-1 from Western blotting. ( L ) Corresponding statistical analysis of ZO-1 from Western blotting. ( M ) Immunofluorescent staining of occludin in ileum. ( N ) Immunofluorescent staining of claudin-1 in ileum. ( O ) Immunofluorescent staining of ZO-1 in ileum. ( P ) Immunofluorescent staining of occludin in colon. ( Q ) Immunofluorescent staining of claudin-1 in colon. ( R ) Immunofluorescent staining of ZO-1 in colon. * P < 0.05, ** P < 0.01 vs NC. # P < 0.05, ## P < 0.01 vs OLA. Scale bar was 200 µm.
Article Snippet: Antibody against GLUT5 (TD13545) was bought from Abmart Medical Technology (Shanghai) Co., Ltd. Take pictures with the pathological section scanner and mean of IOD was used to analyze the results.
Techniques: Staining, Western Blot